Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Effect of cyp2d6, cyp3a5 and mdr1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety

  • At: 2009 FIP Congress in Istanbul (Turkey)
  • Type: Poster
  • By: CUI, Yimin (Department of Pharmacy, Peking University First Hospital, Beijing, China)
  • Co-author(s): Xiang, Qian (Department of Pharmacy, Peking University First Hospital, BEIJING, China)
    Zhao, Xia (Department of Pharmacy, Peking University First Hospital, BEIJING, China)
    Zhou, Ying (Department of Pharmacy, Peking University First Hospital, BEIJING, China)
    Duan, Jingli (Peking University Third Hospital, BEIJING, China)
  • Abstract:

    AIMS

    Clinical studies suggest that plasma levels of risperidone and its active moiety (risperidone + 9-hydroxyrisperidone) correlate with adverse drug effects. The aim of this study was to evaluate the pharmacogenetic variability in the disposition of risperidone and the active moiety in healthy Chinese subjects.

    METHODS

    A two milligram..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses